Matthew J. Mimiaga

Current Academic Appointments. Dr. Matthew J. Mimiaga is tenured Full Professor and Vice Chair of Epidemiology at UCLA Fielding School of Public Health and Psychiatry & Biobehavioral Sciences at UCLA David Geffen School of Medicine, Los Angeles, CA. He is Director of the UCLA Center for LGBTQ+ Advocacy, Research & Health (C- LARAH) and affiliated Senior Research Scientist at The Fenway Institute, Fenway Health, Boston, MA. He is also Adjunct Professor of Epidemiology and Behavioral & Social Sciences at Brown University School of Public Health, Providence, RI.

Previous Academic Appointments. Before joining UCLA in 2020, Dr. Mimiaga was tenured Professor of Epidemiology and Behavioral & Social Health Sciences (School of Public Health) and Professor of Psychiatry & Human Behavior (Alpert Medical School) at Brown University, Providence, RI (from 2015 – 2020). Prior to his appointment at Brown University, he was Professor of Epidemiology at Harvard T.H. Chan School of Public Health and Professor of Psychiatry at Harvard Medical School, Boston, MA (from 2008 – 2015).

Education & Training. Dr. Mimiaga completed the Postdoctoral Research Fellowship Training Program in Behavioral Medicine, Department of Psychiatry, Harvard Medical School; he received a Doctorate of Science from Harvard University, a Master of Public Health from Boston University, and a Master of Arts from Brown University.

Scholarship & Research Awards

Scholarship & Editorial Activities. To date, Dr. Mimiaga has authored over 370 peer-reviewed, original scientific journal articles in the areas of infectious disease/HIV epidemiology, mental health, substance use and public health, including numerous book chapters and commentaries. Dr. Mimiaga is Deputy Editor for the Journal of the International AIDS Society (JIAS); Academic Editor for PLOS ONE; Senior Associate Editor for Annals of LGBTQ Public and Population Health; and currently on the editorial boards of 8 scientific journals (e.g., PLOS ONE, AIDS Care, Transgender Health, JIAS).

Mimiaga's PUBMED page & Google Scholar profile

Research Funding as PI. Dr. Mimiaga is / has been the principal investigator (PI) of several federally funded research grants. These include 21 NIH-funded R- and U-level grants (7 R01s, 1 R56, 6 R34s, 4 R21s, 1 R03, and 2 U01s), two CDC-funded U01 grants, and greater than 35 additional research grants via MA and RI State Departments of Public Health; private foundations (e.g., amfAR); Center For AIDS Research (CFAR) sites at: a) Harvard, b) Brown/Lifespan & BU/Boston Medical Center, and c) UCLA; Harvard Catalyst Grant Program; The Watson Institute Grant Program at Brown; Brown Seed Award Program; The Reagan Institute of MGH, MIT and Harvard; NIH administrative and diversity supplements (8 total); and other university-supported funding opportunities. Dr. Mimiaga previously served as a standing member of the National Institutes of Health HIV/AIDS Intra- and Inter-personal Determinants and Behavioral Intervention (HIBI) Study Section and as a standing member of the Behavioral and Social Consequences of HIV/AIDS (BSCH) Study Section from 2012- 2019.

Mimiaga's Active NIH Funded Grants as PI

Primary Mentor on Funded Research. Dr. Mimiaga is / has been the primary mentor on more than 30 NIH pre- and post-doctoral training grants (e.g., R36, NRSA, K-, and T32 awards); CFAR developmental awards; NIH diversity supplements; UCLA graduate student summer grants; UCLA HEALRISE / EDI Fellowship Grants; Robert Wood Johnson Foundation Health Policy Fellowship grants; and an NIH COBRE award.

Description of Research Center

UCLA Center for LGBTQ+ Advocacy, Research & Health. The mission of the UCLA Center for LGBTQ+ Advocacy, Research & Health, which Dr. Mimiaga directs, is to maintain an interdisciplinary, research-driven, evidence-based platform used to carry out public policy initiatives that improve the health and social well-being of sexual and gender minorities. We engage our local and national community, as well as global partners, through cross-culturally informed scholarship, research, advanced academic training, and civic advocacy. We are deeply invested in intercultural competence and the importance of intersectionality of identities and lived experience; we are committed to conducting research to advance LGBTQ+ racial/ethnic health disparities.

Research Interests & Program

Overview. Dr. Mimiaga's research program focuses on improving health disparities and health equity among a variety of populations—at risk for HIV and other emerging infectious diseases—such as marginalized and disenfranchised groups with vulnerabilities to health disparities or stigmatized conditions, including sexual and gender minorities, racial/ethnic minorities, and other groups that experience social, political, economic, and/or environmental disadvantage. Dr. Mimiaga's research includes developing and testing HIV primary and secondary prevention interventions; biobehavioral interventions to enhance antiretroviral medication uptake and adherence for both HIV treatment (ART) and prevention (PrEP and PEP); psychosocial treatment interventions for stimulant use disorder and concurrent HIV risk, and opioid use disorder and adherence to medication-assisted treatment; infectious disease and psychiatric epidemiology; and global health research in resource constrained countries across the globe.

Dr. Mimiaga's Research Program Includes:

• HIV Primary & Secondary Biobehavioral Prevention: Developing and testing interventions to mitigate HIV risk with antiretrovirals. Current studies include interventions focused on: a) pre-exposure prophylaxis (PrEP) uptake, adherence, and retention in PrEP-related care (once-daily oral pill—emtricitabine/tenofovir (i.e., TRUVADA® or DESCOVY® or an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB))—as PrEP for the prevention of HIV in uninfected individuals); b) post-exposure prophylaxis (PEP, for prevention of HIV after sexual, injection drug use or occupational exposure) phase 4 investigations to document tolerability, toxicity, side effects, and completion rates with newer antiretroviral formulations; and c) antiretroviral therapy (ART, for HIV treatment among individuals living with HIV) uptake and adherence, and retention in HIV care.

• Epidemiology of HIV & Other Emerging Infectious Diseases: This includes documenting the prevalence, incidence, determinants (psychosocial, behavioral, biological and structural), emergence, and transmission of HIV and other sexually transmitted infections (STI), as well as emerging infectious diseases, such as COVID-19 and Monkeypox in various at-risk populations; longitudinal population-based studies to define transmission dynamics and spectrum of disease and survival; characterizing social, sexual and drug use networks to better understand how connections (e.g., homophily, multiplexity), distributions (e.g., centrality, density), and segmentation (e.g., cohesion) potentiates infectious disease risk, acquisition, and transmission; and agent- based modeling to estimate how micro-level processes generate and influence macro- level phenomenon.

• Treatment Approaches for Drug Addiction & Concurrent HIV Risk: Developing and testing integrated psychosocial addiction treatment [e.g., behavioral activation (BA)] and HIV risk reduction interventions for stimulant and opioid use disorders. For example, problematic stimulant (i.e., crystal methamphetamine, cocaine, crack) use is a complex and treatment-resistant problem. One potential contributor to its intractability may be that existing treatments lack adequate attention to replacement activities or to the role of depressed mood/anhedonia relapse trigger, which is the cornerstone of a BA approach. BA is an evidence-based, cognitive behavior therapy approach for depression that involves re-learning how to engage in life by identifying and actively participating in pleasurable, goal-directed activities. The underlying hypothesis, for individuals abusing stimulants, is that re-learning how to engage in the non-drug using aspects of one’s life will facilitate their ability to benefit from concomitant HIV risk reduction counseling.

• Behavioral Interventions for HIV Prevention: Prevention: Development, evaluation, and implementation of interventions to modify behaviors that heighten an individual's vulnerability to HIV acquisition or transmission.  This includes interventions aimed at increasing use of condoms and reducing higher risk sexual behaviors while taking individual characteristics into account, as well as their social, cultural, and economic context. Innovative approaches for delivering intervention content includes the use of technology (e.g., mobile phone counseling, text messaging, mobile apps, interactive video games using avatars, etc.). In addition, often times interventions will address the specific psychosocial problems that exacerbate HIV risks, such as empowerment, self-acceptance, and distress. Addressing these psychosocial problems as part of an HIV prevention intervention is a way to help individuals who suffer the damaging impact of adverse social conditions that they face—resulting in decreased distress and increased self-care—therefore promoting their ability to benefit from HIV prevention efforts.

• Global Health: Conducting HIV prevention research that advances health among myriad at-risk populations in resource-limited settings. Current studies are being conducted in Asia, Africa, North America, Latin America, and Eastern Europe. Dr. Mimiaga's prior population- based studies have surveyed at-risk groups via the internet--spanning all Latin American countries, North America, Spain, Portugal, and Vietnam--to better understand risk and protective factors for HIV infection.

• Health & Human Rights: Documenting the epidemiology of violence, exploitation, abuse, neglect, substance use, and poor psychological well-being and access to medical, mental health and social services among adolescent refugees in Sub-Saharan Africa and Latin America, with the goal of developing and testing behavioral- and structural-level interventions to promote healthier conditions.

UCLA Committee Participation

1. Standing Member, UCLA South General Institutional Review Board (IRB); meets biweekly
2. Faculty Member, Department of Epidemiology Doctoral Admissions Committee
3. Executive Committee Member, UCLA Center for AIDS Research (CFAR)
4. Reviewer, UCLA Eugene V. Cota-Robles Fellowship Program (University-wide) (DIV)
5. Reviewer, UCLA Graduate Opportunity Fellowship Program (GOFP) (University-wide) (DIV)
6. Chair (temporary), Appointments and Promotions Committee, Department of Epidemiology, UCLA FSPH
7. Chair, Equity, Diversity and Inclusion Committee, Department of Epidemiology, UCLA FSPH (DIV)
8. Legislative Assembly Representatives for the Department of Epidemiology, UCLA Academic Senate
9. Member, UCLA Equity, Diversity and Inclusion Task Force (University-wide) (DIV)
10. Co-Chair, Department of Epidemiology MPH/MS Admissions Committee
11. Chair, Epidemiology Seminar Series Committee
12. Chair, MPH APE/ILE Committees

Selected Publications

Mimiaga's PUBMED page and Google Scholar Profile